NextCure, Inc. (NXTC) · Nov 20, 2026 · Other events
CVR distribution scheduled — Record date Dec. 8; expected distribution Dec. 14
NextCure’s 8-K sets the December 8 record date and expected December 14 CVR distribution ahead of its Avere merger.
NextCure is transitioning away from its legacy oncology business and toward Avere’s oral IL-23 drug platform through a proposed merger, with the combined company expected to operate as Avere and supported by roughly $820 million of committed financing. This filing advances the transaction administratively, not economically. The board set December 8, 2026 as the record date and expects the contingent value rights to be distributed on December 14, 2026, one business day after the anticipated first merger effective time. 〔0〕
The CVR structure preserves a defined claim on legacy-asset monetization, but this 8-K does not create new value or improve the merger terms. Each CVR covers 90% of gross proceeds, if any, from qualifying future sales, transfers, licenses or other dispositions of pre-merger assets, after permitted deductions. The direction and existence of that protection were already disclosed in the merger materials; the new information is simply the timetable, and payment remains conditioned on the merger actually closing.
Bottom line: This is a routine closing-schedule confirmation for an already-known merger, not a change to NextCure’s business story or the CVR economics. The next meaningful event is the December 9 stockholder vote and whether the transaction closes as expected on December 14.
Stockholder vote Dec. 9; anticipated merger closing Dec. 14
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!